Cargo Therapeutics, Inc. (NASDAQ:CRGX) is a company involved in the development of innovative therapies. Recently, the company has been under scrutiny due to significant changes in its stock price and investor sentiment. As of January 30, 2025, Truist Financial's analyst Asthika Goonewardene set a price target of $7 for CRGX, while the stock was trading at $13.19. This target suggests a potential decrease of approximately 46.93%.
The downgrade from a Buy to a Hold by Truist, as reported by TheFly, reflects a cautious stance on CRGX's future performance. This downgrade aligns with the ongoing investigation by Bronstein, Gewirtz & Grossman, LLC into potential claims on behalf of investors who purchased CRGX securities. The law firm is actively encouraging investors to participate in this investigation, indicating potential concerns about the company's operations or financial disclosures.
CRGX's stock has experienced a dramatic decline, currently priced at $3.35, marking a 74.60% decrease from its previous value. This drop of $9.84 highlights the volatility and uncertainty surrounding the stock. The stock's fluctuation today, with a low of $3 and a high of $3.45, further emphasizes the market's reaction to recent developments.
Over the past year, CRGX has seen a high of $33.92 and a low of $3, showcasing the stock's significant volatility. The company's market capitalization is approximately $154.19 million, reflecting the impact of the stock's decline on its overall valuation. With a trading volume of 15,690,781 shares on the NASDAQ exchange today, investor interest remains high despite the challenges faced by the company.
Read More